What We Do Leadership Therapeutic Areas Partnering News Contact
moksha8 Pharmaceuticals and CheplaPharm completed a strategic partnership to distribute Questran in Mexico and Brazil
October 31st, 2018
moksha8 Pharmaceuticals and the Germany Laboratory, CHEPLAPHARM Arzneimittel GmbH, have signed an agreement in which moksha8 will commercialize and promote Questran in Mexico and Brazil.
Questran (Cholestyramine) is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low-density lipoprotein [LDL] cholesterol).
High level of cholesterol increases the risks of heart disease and stroke. Globally, a third of ischaemic heart disease is attributable to high cholesterol. Overall, hypercholesterolemia is estimated to cause 2.6 million deaths. Prevalence High cholesterol among adults is 39% worldwide (37% for males and 40% for females) the highest prevalence according to WHO is Europe (54% for both sexes), followed by the Americas (48% for both sexes).
In Latin America, lipid abnormalities have a high prevalence and this is related to multiple causes: genetic load and epigenetic modifications combined with a sedentary lifestyle and an inadequate nutrition*.
Questran (Cholestyramine) has proven if is used along with a proper diet to lower cholesterol in the blood. Lowering cholesterol helps decrease the risk for strokes and heart attacks.
moksha8 and CheplaPharm have an established great partnership since last year with the distribution agreement for Dilatrend in Mexico and, due to the positive results achieved, the companies decided to expand their commercial relationship in the South American country.
With this agreement, moksha8 Pharmaceuticals continues with its global diversification strategy and is increasing its cardiology portfolio. In Mexico, Questran is the second product in the cardiology line and in the case of Brazil, Questran will be the therapy with which the subsidiary will enter into the therapeutic area.
moksha8 is committed to work hard to maximize the product value of Questran and further contribute to hypercholesterolemia treatments in the LA region.
* World Health Organization/cholesterol, 2011
COPYRIGHT © 2006-2019 MOKSHA8 PHARMACEUTICALS, INC. ALL RIGHTS RESERVED. THIS INFORMATION—INCLUDING PRODUCT INFORMATION—IS INTENDED ONLY FOR RESIDENTS OF THE UNITED STATES. THE PRODUCTS DISCUSSED HEREIN MAY HAVE DIFFERENT LABELING IN DIFFERENT COUNTRIES.
What We Do
COPYRIGHT © 2006-2019 MOKSHA8 PHARMACEUTICALS, INC. ALL RIGHTS RESERVED. This information—including product information—is intended only for residents of the united states. The products discussed herein may have different labeling in different countries.